| Abstrakt: |
A new standard chemotherapy for ovarian cancer has been accepted in the USA: paclitaxel (Taxol®) plus a platinum compound (cisplatin or carboplatin). There remain, however, many areas of controversy in treating this disease, including the role of cytoreductive surgery, the optimum combination regimen, the approach to managing patients who achieve a clinical remission, the importance of dose intensity in chemotherapy, the efficacy of intraperitoneal therapy, the benefit of whole-abdomen irradiation, and the status of immunotherapy and hormones. [ABSTRACT FROM AUTHOR] |
Plný text